GlucoBeam: A portable device for pain-free glucose self-monitoring in diabetic patients

Información del proyecto

GlucoBeam

Identificador del acuerdo de subvención: 738973

DOI

10.3030/738973

Proyecto cerrado

Fecha de la firma de la CE 26 Febrero 2017

Fecha de inicio 1 Marzo 2017

Fecha de finalización 30 Septiembre 2021

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total

€ 5 219 875,00

Aportación de la UE

€ 2 348 943,75

Coordinado por

RSP SYSTEMS A/S
Denmark

Objetivo

Diabetes mellitus (DM) is one of the largest health challenges currently faced by modern society, affecting over 400 million people in the world. DM cannot be cured, but via well-controlled therapy, a high quality of life with diabetes can be obtained, with a minimum of short- and long-term complications. The key to a successful diabetes therapy is a well-controlled blood glucose level, which is obtained by carefully balancing insulin intake, diet, and exercise and with Self-Monitoring of Blood Glucose (SMBG) as a cornerstone. Conventional SMBG is an invasive test requiring the patient to prick his/her finger with a lancet to extract a blood droplet onto a disposable strip for electrochemical analysis of the glucose concentration. Repeating this uncomfortable and painful task 4-8 times per day leads to severe loss in life quality, often resulting in poor compliance
leading to costly complications.

RSP’s proprietary non-invasive SMBG technology relies on the capabilities of Raman spectroscopy for directly detecting
individual substances, refined by a unique critical depth optical scanning to collect glucose signals from the right tissue depth
range, thus avoiding sources of errors during the measurement. Our GlucoBeam device will enable DM patients to test their
glucose levels in around 30s and as often as desired – at no added cost or pain – thereby empowering them to better
manage their treatment and minimizing the risk for acute complications.

GlucoBeam’s successful commercialization will position RSP to secure an aggregated turnover of approx. €253 million over
the 5 years post-project period. Furthermore, it has the potential to reach double digit billion savings for EU’s healthcare
systems and will ultimately lead to significantly improved life quality for the large population of diabetic patients. Moreover,
GlucoBeam’s commercialization will allow RSP to set a market foothold in order to leverage its medium term innovation
strategy.

Ámbito científico (EuroSciVoc)

• ciencias naturales › informática y ciencias de la información › ciencia de datos
• ciencias médicas y de la salud › medicina clínica › endocrinología › diabetes
• ciencias médicas y de la salud › ciencias de la salud › nutrición
• ciencias naturales › ciencias físicas › óptica › espectroscopia

Palabras clave

• Diabetes mellitus
• Self-Monitoring of Blood Glucose
• Non-invasive testing
• Raman Spectroscopy

Programa(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being PROGRAMA PRINCIPAL
  
• H2020-EU.3.1.4. - Active ageing and self-management of health
  
• H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
  
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
  
• H2020-EU.3.1.6. - Health care provision and integrated care
  

Tema(s)

• SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well
  

Régimen de financiación

SME-2 - SME instrument phase 2

Convocatoria de propuestas

H2020-SMEInst-2016-2017

Coordinador

RSP SYSTEMS A/S

• Aportación neta de la UEn: € 2 348 943,75
• Dirección: SIVLANDAENGET 27 C HJALLESE ; 5260 Odense S ; Dinamarca
• Pyme Sí:
  Región
  Danmark › Syddanmark › Fyn
• Región: Danmark › Syddanmark › Fyn
• Tipo de actividad: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Coste total: € 5 219 875,00